^
Association details:
| Biomarker: | CD74-ROS1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A case of CD74-ROS1-positive lung adenocarcinoma diagnosed by next-generation sequencing achieved long-term survival with pemetrexed regimens
Published date:
07/24/2023
Excerpt:
A 54-year-old woman with left anterior chest pain had been diagnosed with left lower lung adenocarcinoma 11 years ago....Foundation One CDx revealed CD74-ROS1 fusion (Figure 4). Therefore, the patient was administered entrectinib as the ninth treatment line, which significantly reduced the right cervical lymphadenopathy and right lower tumors. She has been taking entrectinib for over 20 months now.
DOI:
https://doi.org/10.1111/1759-7714.15041
Test:
Source:
Title:
A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
Published date:
07/28/2021
Excerpt:
We present a case of lung adenocarcinoma with a previously unknown ROS1-CD74 fusion variant...This tumor responded to crizotinib initially and to entrectinib after relapse with brain metastasis, indicating the oncogenic activity of this novel fusion variant.
DOI:
https://doi.org/10.1111/1759-7714.14093
